| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 10 | 20 | 30 | 30 | 100 |
| Sales Growth | -50.00% | -33.33% | unch | -70.00% | unch |
| Net Income | -910 | -3,690 | -3,600 | -1,580 | -3,740 |
| Net Income Growth | +75.34% | -2.50% | -127.85% | +57.75% | -50.20% |
Nanomix Corp (NNMXD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nanomix Corporation is involved in the development of mobile, affordable, point-of-care diagnostics. The company's products are designed to impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings. Nanomix Corporation, formerly known as Boston Therapeutics Inc., is based in EMERYVILLE, Calif.